[go: up one dir, main page]

CO2017005374A2 - Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation - Google Patents

Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation

Info

Publication number
CO2017005374A2
CO2017005374A2 CONC2017/0005374A CO2017005374A CO2017005374A2 CO 2017005374 A2 CO2017005374 A2 CO 2017005374A2 CO 2017005374 A CO2017005374 A CO 2017005374A CO 2017005374 A2 CO2017005374 A2 CO 2017005374A2
Authority
CO
Colombia
Prior art keywords
preparation
diseases
endometriosis
prevention
irak4
Prior art date
Application number
CONC2017/0005374A
Other languages
Spanish (es)
Inventor
Ulf Bömer
Reinhard Nubbemeyer
Christian Stegmann
Ulrich Bothe
Holger Siebeneicher
Nicole Schmidt
Judith Günther
Holger Steuber
Martin Lange
Andreas Sutter
Alexandra Rausch
Christian Friedrich
Peter Hauff
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CO2017005374A2 publication Critical patent/CO2017005374A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere a nuevos indazoles sustituidos, procedimientos para su preparación, su uso solos o en combinaciones para el tratamiento y/o prevención de enfermedades, así como su uso para la preparación de medicamentos para el tratamiento y/o prevención de enfermedades, en especial para el tratamiento y/o la prevención de endometriosis, así como dolores asociados con endometriosis y otros síntomas asociados con endometriosis como dismenorrea, dispareunia, disuria y disquecia, de linfomas, artritis reumatoidea, espondiloartritis (en especial espondiloartritis psoriásica y enfermedad de Bechterew), lupus eritematoso, esclerosis múltiple, degeneración macular, EPOC, gota, enfermedades de hígado graso, insuficiencia insulínica, enfermedades tumorales y psoriasis.This application refers to new substituted indazoles, procedures for their preparation, their use alone or in combinations for the treatment and / or prevention of diseases, as well as their use for the preparation of drugs for the treatment and / or prevention of diseases, especially for the treatment and / or prevention of endometriosis, as well as pain associated with endometriosis and other symptoms associated with endometriosis such as dysmenorrhea, dyspareunia, dysuria and dyschecia, lymphomas, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bechterew's disease ), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver diseases, insulin insufficiency, tumor diseases and psoriasis.

CONC2017/0005374A 2014-11-26 2017-06-26 Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation CO2017005374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26
PCT/EP2015/077596 WO2016083433A1 (en) 2014-11-26 2015-11-25 New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

Publications (1)

Publication Number Publication Date
CO2017005374A2 true CO2017005374A2 (en) 2017-08-31

Family

ID=51982455

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005374A CO2017005374A2 (en) 2014-11-26 2017-06-26 Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation

Country Status (42)

Country Link
US (6) US10308634B2 (en)
EP (3) EP3674298B9 (en)
JP (1) JP6496823B2 (en)
KR (1) KR102083857B1 (en)
CN (2) CN110305109B (en)
AR (1) AR102827A1 (en)
AU (2) AU2015352603B2 (en)
BR (2) BR122021002613B1 (en)
CA (1) CA2968614C (en)
CL (1) CL2017001364A1 (en)
CO (1) CO2017005374A2 (en)
CR (1) CR20170220A (en)
CU (1) CU24448B1 (en)
CY (1) CY1123815T1 (en)
DK (2) DK3674298T3 (en)
DO (1) DOP2017000127A (en)
EA (1) EA032509B1 (en)
EC (1) ECSP17032530A (en)
ES (2) ES2796285T3 (en)
FI (1) FI3674298T3 (en)
HR (2) HRP20240414T1 (en)
HU (2) HUE065938T2 (en)
IL (3) IL252185B (en)
JO (1) JO3705B1 (en)
LT (2) LT3224254T (en)
MA (1) MA41011B1 (en)
ME (1) ME03745B (en)
MX (2) MX380150B (en)
NI (1) NI201700063A (en)
NZ (1) NZ732126A (en)
PE (1) PE20171376A1 (en)
PH (1) PH12017500972A1 (en)
PL (2) PL3224254T3 (en)
PT (2) PT3224254T (en)
RS (2) RS60284B1 (en)
SG (3) SG10201903474PA (en)
SI (2) SI3674298T1 (en)
TN (1) TN2017000226A1 (en)
TW (2) TWI717061B (en)
UA (2) UA123813C2 (en)
UY (1) UY36411A (en)
WO (1) WO2016083433A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999710B2 (en) 2018-06-27 2024-06-04 Hoffmann-La Roche Inc. Radiolabeled cannabinoid receptor 2 ligand
US12071420B2 (en) 2018-06-27 2024-08-27 Hoffmann-La Roche Inc. Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US12180196B2 (en) 2018-06-27 2024-12-31 Hoffmann-La Roche Inc. Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
EP3805233B1 (en) 2014-01-13 2024-03-06 Aurigene Oncology Limited (r) and (s) enantiomers of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for the treatment of cancer
JO3705B1 (en) * 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
EP3195865A1 (en) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2984259C (en) * 2015-04-30 2024-02-13 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3310786B1 (en) 2015-06-16 2021-03-03 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
EP3423446B1 (en) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
EA035867B1 (en) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Synthesis of indazoles
HRP20231454T1 (en) 2016-04-29 2024-03-01 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
AU2017256659B2 (en) * 2016-04-29 2021-05-27 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
AU2017273771B2 (en) * 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
UA124237C2 (en) * 2016-06-01 2021-08-11 Байєр Енімал Хелс Гмбх Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
AR109595A1 (en) 2016-09-09 2018-12-26 Incyte Corp PIRAZOLOPIRIMIDINE COMPOUNDS AND USES OF THESE AS HPK1 INHIBITORS
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AU2017322427B2 (en) 2016-09-09 2021-12-23 Incyte Corporation Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer
WO2018060072A1 (en) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft New substituted benzimidazoles, methods for the production of same, pharmaceutical preparations containing same, and use of same to produce drugs
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc Perulo derivatives [1, 2-b] pyridazine
IL269536B (en) 2017-03-31 2022-07-01 Aurigene Discovery Tech Ltd Compounds and compositions for treating hematological disorders
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
SG11202001264UA (en) 2017-08-16 2020-03-30 Univ Vanderbilt Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
BR112020013672A2 (en) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compounds, compositions, and methods for treating diseases involving tissues affected by acids or hypoxia
BR112020016927A2 (en) 2018-02-20 2020-12-15 Incyte Corporation N- (PHENYL) -2- (PHENYL) PYRIMIDIN-4-CARBOXAMIDE DERIVATIVES AND COMPOUNDS RELATED TO HPK1 INHIBITORS TO TREAT CANCER
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
TWI842978B (en) 2018-07-13 2024-05-21 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN110835338A (en) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 Imidazopyridine derivative, preparation method and medical application thereof
US11897863B2 (en) 2018-08-17 2024-02-13 Zhejiang Hisun Pharmaceutical Co., Ltd. Indazole amine derivative, preparation method therefor and medical use thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
EP3889150A4 (en) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. Compound serving as irak inhibitor
CN111362920B (en) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 Compound as IRAK inhibitor
CN111499612B (en) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 Compound as IRAK inhibitor and preparation method and application thereof
CN111560012B (en) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 Compound as IRAK inhibitor
CN111793064B (en) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 Compound serving as IRAK inhibitor as well as preparation method and application thereof
CN113825755B (en) * 2019-06-26 2023-04-25 南京明德新药研发有限公司 Imidazolopyridines as IRAK4 Inhibitors
MA56392A (en) * 2019-06-27 2022-05-04 Biogen Ma Inc 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
TW202116778A (en) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 Peptide conjugates of cytotoxins as therapeutics
BR112022000297A2 (en) 2019-07-10 2022-03-15 Cybrexa 3 Inc Peptide conjugates of microtubule targeting agents as therapeutics
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
PE20221419A1 (en) 2019-08-06 2022-09-20 Incyte Corp SOLID FORMS OF AN HPK1 INHIBITOR
NZ786493A (en) * 2019-09-24 2025-06-27 Wuhan Createrna Science And Tech Co Ltd Irak inhibitor and preparation method therefor and use thereof
CN111072634B (en) * 2020-01-03 2022-07-22 中国医科大学 1-substituted-3-substituted-5-substituted amide-1H-indole compound and preparation method and application thereof
CN113521079A (en) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Use of IRAK4 inhibitors for the treatment of ALI/ARDS
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
BR112023020669A2 (en) 2021-04-08 2023-12-12 Curis Inc COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN113278017B (en) * 2021-05-27 2023-03-28 上海应用技术大学 Substituted indazoles, preparation method, application and composition containing same
CN113402499B (en) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 Sulfimide substituted indazole IRAK4 kinase inhibitor, preparation method and application
US20250018046A1 (en) * 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
CN118302425A (en) * 2021-12-03 2024-07-05 武汉人福创新药物研发中心有限公司 IRAK4 inhibitors and uses thereof
CN119894895A (en) 2022-11-04 2025-04-25 领泰生物医药(绍兴)有限公司 IRAK4 degradation agent and application thereof
KR20250108621A (en) * 2022-11-17 2025-07-15 엘랑코 애니멀 헬스 게엄베하 Methods and compositions for controlling pain and inflammation
CN116120283B (en) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 A deuterated pyridine amide IRAK-4 inhibitor drug and its use
KR20250004525A (en) * 2023-06-29 2025-01-08 동화약품주식회사 Novel Carboxamide Derivative Compound and Pharmaceutical Composition Comprising the Same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (en) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. SEMI-SUBMERSIBLE SELF-PROMISED UNIT FOR TRANSPORTATION AND LIVING OF LIVING FISH.
JP4777648B2 (en) * 2002-07-31 2011-09-21 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト VEGFR-2 and VEGFR-3 inhibitory anthranilamidopyridine
CA2531543C (en) 2003-06-25 2010-10-12 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
EP1828133A2 (en) 2004-12-08 2007-09-05 Warner-Lambert Company LLC Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GT200600411A (en) 2005-09-13 2007-05-21 Novartis Ag COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
AU2007213452A1 (en) 2006-02-10 2007-08-16 Biomarin Iga Limited Treatment of Duchenne muscular dystrophy
TWI435863B (en) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd N-2-(hetero) arylethylcarboxamide derivative and pest controlling
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
MX2009002377A (en) * 2006-09-07 2009-03-13 Biogen Idec Inc Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase.
FR2917735B1 (en) 2007-06-21 2009-09-04 Sanofi Aventis Sa NEW SUBSTITUTED INDAZOLES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
EP2507226A1 (en) * 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
CA2822166C (en) * 2010-12-20 2019-10-29 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
BR112013020270A2 (en) 2011-02-10 2016-07-12 Syngenta Participations Ag pyrazole derivatives microbicides
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
WO2013174744A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP2015002717A (en) 2013-06-21 2015-01-08 住友ベークライト株式会社 Container with lid
TWI667233B (en) 2013-12-19 2019-08-01 德商拜耳製藥公司 Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
EA201692418A1 (en) 2014-06-20 2017-04-28 Ауриджен Дискавери Текнолоджиз Лимитед SUBSTITUTE INDASOLIC COMPOUNDS AS IRAK4 INHIBITORS
JO3705B1 (en) * 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
CA2984259C (en) 2015-04-30 2024-02-13 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3423446B1 (en) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
AU2017256659B2 (en) 2016-04-29 2021-05-27 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
HRP20231454T1 (en) 2016-04-29 2024-03-01 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
UA124237C2 (en) 2016-06-01 2021-08-11 Байєр Енімал Хелс Гмбх Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
AU2017273771B2 (en) 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999710B2 (en) 2018-06-27 2024-06-04 Hoffmann-La Roche Inc. Radiolabeled cannabinoid receptor 2 ligand
US12071420B2 (en) 2018-06-27 2024-08-27 Hoffmann-La Roche Inc. Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US12180196B2 (en) 2018-06-27 2024-12-31 Hoffmann-La Roche Inc. Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Also Published As

Publication number Publication date
EP3674298B9 (en) 2024-06-19
CN110305109B (en) 2022-04-08
US10308634B2 (en) 2019-06-04
CU24448B1 (en) 2019-10-04
BR112017011005B1 (en) 2023-03-14
HUE065938T2 (en) 2024-06-28
PT3674298T (en) 2024-04-01
EA032509B1 (en) 2019-06-28
EP3674298B1 (en) 2024-01-10
HRP20240414T1 (en) 2024-06-21
AU2020200979B2 (en) 2021-01-07
PT3224254T (en) 2020-06-17
IL267537A (en) 2019-08-29
EP3224254B1 (en) 2020-04-15
JP2017535585A (en) 2017-11-30
UA120948C2 (en) 2020-03-10
DOP2017000127A (en) 2017-07-31
LT3224254T (en) 2020-06-10
SG11201704092YA (en) 2017-06-29
TW202002973A (en) 2020-01-16
EP3674298A1 (en) 2020-07-01
AU2020200979A1 (en) 2020-02-27
AR102827A1 (en) 2017-03-29
CA2968614C (en) 2019-10-29
SG10201903474PA (en) 2019-05-30
ES2976932T3 (en) 2024-08-13
MX390119B (en) 2025-03-20
BR122021002613B1 (en) 2023-04-11
PL3674298T3 (en) 2024-06-24
SI3224254T1 (en) 2020-07-31
US20220388982A1 (en) 2022-12-08
SI3674298T1 (en) 2024-05-31
DK3224254T3 (en) 2020-07-13
TW201629037A (en) 2016-08-16
IL267537B (en) 2020-07-30
WO2016083433A1 (en) 2016-06-02
TWI689502B (en) 2020-04-01
ME03745B (en) 2021-04-20
BR112017011005A2 (en) 2019-05-14
MX2017006910A (en) 2017-08-15
ES2796285T3 (en) 2020-11-26
MA41011B1 (en) 2020-08-31
KR102083857B1 (en) 2020-03-03
US20170349570A1 (en) 2017-12-07
HRP20200974T1 (en) 2020-10-02
LT3674298T (en) 2024-04-10
US10793545B2 (en) 2020-10-06
ES2976932T9 (en) 2024-09-05
DK3674298T3 (en) 2024-04-08
FI3674298T3 (en) 2024-04-17
EP4260909A2 (en) 2023-10-18
TN2017000226A1 (en) 2018-10-19
CA2968614A1 (en) 2016-06-02
SG10201903475TA (en) 2019-05-30
CY1123815T1 (en) 2022-03-24
CU20170073A7 (en) 2017-10-05
ECSP17032530A (en) 2017-06-30
CN110305109A (en) 2019-10-08
TWI717061B (en) 2021-01-21
MX2020010623A (en) 2022-02-16
IL252185B (en) 2019-10-31
US20250034111A1 (en) 2025-01-30
UA123813C2 (en) 2021-06-02
PL3224254T3 (en) 2020-09-21
IL269444B (en) 2020-07-30
AU2015352603B2 (en) 2020-04-02
KR20170085590A (en) 2017-07-24
NI201700063A (en) 2017-07-17
UY36411A (en) 2016-06-30
US20210053941A1 (en) 2021-02-25
MX380150B (en) 2025-03-12
RS60284B1 (en) 2020-06-30
EA201791137A1 (en) 2017-11-30
IL269444A (en) 2019-11-28
EP3224254A1 (en) 2017-10-04
AU2015352603A1 (en) 2017-06-01
CR20170220A (en) 2017-10-31
NZ732126A (en) 2018-09-28
US20230174508A1 (en) 2023-06-08
JP6496823B2 (en) 2019-04-10
RS65327B1 (en) 2024-04-30
JO3705B1 (en) 2021-01-31
CL2017001364A1 (en) 2017-12-15
US12006303B2 (en) 2024-06-11
CN107406416B (en) 2020-04-21
US20190233395A1 (en) 2019-08-01
EP4260909A3 (en) 2024-03-20
IL252185A0 (en) 2017-07-31
US12006304B2 (en) 2024-06-11
HUE049341T2 (en) 2020-09-28
PE20171376A1 (en) 2017-09-15
PH12017500972A1 (en) 2017-12-18
CN107406416A (en) 2017-11-28

Similar Documents

Publication Publication Date Title
CO2017005374A2 (en) Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation
UY37048A (en) NEW REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
UY37142A (en) NEW 2-REPLACED INDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CY1121843T1 (en) MAGNESIUM ION STABILIZED RECEPTOR FORMULATIONS
BR112019000327A8 (en) ANTICLAUDIN 18A2 ANTIBODY AND USE THEREOF
PH12022550194A1 (en) Anti-gitr antibodies and methods of use thereof
EA201792047A1 (en) NEW CONNECTIONS
GT201600147A (en) DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2
CL2014000114A1 (en) Antibody that binds to human r-spondin 1 (rspo1); polypeptide comprising an antibody; pharmaceutical composition comprising the antibody; use to inhibit the growth of a tumor.
CL2014000746A1 (en) Compounds derived from 3-pyrimidin-4-yl-oxazolidin-2-one and their salts, as inhibitors of the mutant idh proteins; pharmaceutical composition that includes them, useful for the treatment of disorders of cell proliferation such as cancer.
MX391015B (en) NANOPARTICLE COMPOSITIONS AND THEIR USES
EA201691484A1 (en) SALT AND SOLID FORM OF BTK INHIBITOR
MX2017014908A (en) Trispecific binding proteins and methods of use.
PE20151070A1 (en) TYROSINE INHIBITORS - BRUTON KINASE
MX381180B (en) AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES.
MX2022015250A (en) AN ANTI-IL-23A ANTIBODY FOR USE IN THE TREATMENT OF CROHN'S DISEASE.
CL2017002082A1 (en) New specific proteins for pioverdine and pyoquelin
MX2016010848A (en) 1,2-substituted cyclopentanes as orexin receptor antagonists.
MX2017001553A (en) OPTIONALLY CONDENSED HETEROCICLIC DERIVED FROM PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC ONCOLOGICAL AND AUTOINMUNITY DISEASES.
UY36224A (en) TRICYCLIC COMPOUNDS OF IMIDAZO-PIRIMIDINONA
CL2019003557A1 (en) Anti-trkb antibodies.
UY37267A (en) NEW SUBSTITUTED BENZIMIDAZOLS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
UY35823A (en) NMDA ANTAGONIST PROPHARMS
BR112016018077A8 (en) cholesteryl ester transfer protein inhibitor (compound a), pharmaceutical compositions comprising the same, method for preparing said compositions and using the compound a
AR103294A1 (en) COMPOSITIONS AND PROCEDURES FOR THE GLYCOSILATION OF PROTEINS